[1]王佳琼,王自正,姚薇萱,等.乳腺肿瘤生长抑素受体表达与生长抑素受体显像[J].国际放射医学核医学杂志,2006,30(1):17-21.
　WANG Jia-qiong,WANG Zi-zheng,YAO Wei-xuan,et al.Somatostatin receptor scintigraphy and somatostatin receptors expression in breast neoplasm[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(1):17-21.
点击复制

乳腺肿瘤生长抑素受体表达与生长抑素受体显像(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
30
期数:
2006年第1期
页码:
17-21
栏目:
实验核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Somatostatin receptor scintigraphy and somatostatin receptors expression in breast neoplasm
作者:
王佳琼;  王自正;  姚薇萱;  王峰
210006 南京, 南京医科大学附属第一医院临床核医学中心
Author(s):
WANG Jia-qiong;  WANG Zi-zheng;  YAO Wei-xuan;  WANG Feng
Department of Nuclear Medicine, Nanjing First Hospital Affiliated to Nanjing Medical University, Nanjing 210006, China
关键词:
乳腺肿瘤; 受体; 生长抑素; 锝; 奥曲肽
Keywords:
Breast cancer; Receptor; somatostatin; Technetium; Octreotide
分类号:
R817.4
摘要:
目的 探讨生长抑素受体(SSTR)显像对乳腺癌的诊断价值。方法 15例乳腺癌患者术前进行99mTc-奥曲肽SSTR显像,勾画感兴趣区,计算瘤体与对侧正常组织的放射性比值(T/N),术后采用逆转录-聚合酶链反应检测肿瘤组织SSTR1-SSTR5 mRNA的表达,SP免疫组化法比较该15例乳腺癌和18例乳腺良性病变组织SSTR2和SSTR5的表达水平。结果 ①15例乳腺癌患者99mTc-奥曲肽SSTR显像均为阳性,T/N为1.873±0.341;②15例乳腺癌组织的SSTR1、SSTR2、SSTR3、SSTR4、SSTR5mRNA表达阳性率分别为100%(15/15)、93.30%(14/15)、100%(15/15)、46.70%(7/15)、86.70%(13/15),以甘油醛-3-磷酸脱氢酶(GAPDH)基因为内参基因计算的mRNA表达量,从高到低分别为SSTR3、SSTR1、SSTR2、SSTR5、SSTR4,SSTR2 mRNA表达水平与乳腺癌显像T/N呈正相关,有显著的统计学意义(r=0.728,P<0.01);③SP免疫组化结果显示,乳腺癌组织的SSTR2和SSTR5的表达明显高于乳腺良性病变组织。结论 乳腺癌组织有丰富的SSTR表达,明显高于乳腺良性病变组织,99mTc-奥曲肽SSTR显像对乳腺癌有较好的靶向诊断价值。
Abstract:
Objective To evaluate the value of 99mTc-octreotide somatostatin receptor (SSTR) scintig-raphy in breast cancer.Methods 15 breast cancer patients underwent 99mTc-octreotide SSTR scintigraphy before surgery, and tumor to normal tissue ratio (T/N) was calculated. mRNA expression of SSTR 1, SSTR2, SSTR3, SSTR4, SSTR5 was detected by RT-PCR after surgery. And SSTR2 and SSTR5 expressions were detected by immunohistochemical staining in these 15 breast carcinoma as well as other 18 benign breast tissue.Results All of the 15 breast cancer patients showed intense uptake of 99mTc-octreotide, and T/N values were 1.873±0.341. All five SSTR sub-types were variably expressed at the mRNA level in breast cancer with 100% (15/15)amplesshowing SSTR1, 93.30% (14/15) SSTR2, 100% (15/15) SSTR3, 46.70% (7/15)SSTR4 and 86.70% (13/15)SSTR5. Levels of SSTR mRNA, when corrected for glyeraldehyde 3-phosphaate dehydrogenase gene levels, were highest for SSTR3 followed by SSTR1, SSTR2, SSTR5, and SSTR4. Good correlation was obtained between the ratio of T/N and the expression of SSTR2 mRNA (r=0.728, P<0.01). Both the expression of SSTR2 and SSTR5 are higher in malignant ones than in benign breast tissues.Conclusion The results indicate that there was high expression of SSTR in breast cancer. SSTR scintigraphy is of great value in targeted detection of breast cancer.

参考文献/References:

1 Zatelli MC,Tagliati F,Taylor JE,et al.Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT.J Clin Endocrinol Metab,2001,86(5):2161-2169.
2 Dolan JT,Miltenburg DM,Granchi TS,et al.Treatment of metastatic breast cancer with somatostatin analogues-a meta-analysis.Ann Surg Oncol,2001,8(3):227-233.
3 Gabriel M,Decristoforo C,Donnemiller E,et al.An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.J Nucl Med,2003,44(5):708-716.
4 De Jong M,Valkema R,Jamar F,et al.Somatostatin receptor-targeted radionuclide therapy of tumors:preclinical and clinical findings.Semin Nucl Med,2002,32(2):133-140.
5 Chiti A,Briganti V,Fanti S,et al.Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumors.Q J Nucl Med,2000,44(1):42-49.
6 Orlando C,Raggi CC,Bianchi S,et al.Measurement of somatostatin receptor subtype 2 mRNA in breast cancer and corresponding normal tissue.Endocr Relat Cancer,2004,11(2):323-332.
7 Schulz S,Helmholz T,Schmitt J,et al.True positive somatostatin receptor scintigraphy in primary breast cancer correlates with expression of sst2A and sst5.Breast Cancer Res Treat,2002,72(3):221-226.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]杨雷,袁卫红,王家平,等.99Tcm-MIBI显像与钼靶X线对乳腺癌诊断的比较研究[J].国际放射医学核医学杂志,2016,40(2):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
　Yang Lei,Yuan Weihong,Wang Jiaping,et al.Diagnostic value of technetium 99Tcm sestamibi and X-ray mammography in breast cancer: a comparison study[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
[3]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
　Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[4]马乐,张万春,李晓敏.乳腺癌前哨淋巴结核素显像新进展[J].国际放射医学核医学杂志,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
　Ma Le,Zhang Wanchun,Li Xiaomin.Evolution of radionuclide imaging of sentinel node lymphscintigraphy in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
[5]储小飞,赵舒怡,樊赛军.肿瘤干细胞与辐射抗性的研究进展[J].国际放射医学核医学杂志,2015,39(5):431.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 019]
　chu xiaofei,zhao shuyi,fan saijun..advance progress of cancer stem cells and radioresistance[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):431.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 019]
[6]陈伟君,孙达.99Tcm-MIBI显像在乳腺癌新辅助化疗中的应用价值[J].国际放射医学核医学杂志,2015,39(6):487.[doi:10.3760/cma.j.issn.1673-4114.2015.06.011]
　Chen Weijun,Sun Da.Clinical value of 99Tcm-MIBI imaging in neoadjuvant chemotherapy of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):487.[doi:10.3760/cma.j.issn.1673-4114.2015.06.011]
[7]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[8]胡鸿,唐刚华,聂大红.乳腺癌分子显像研究进展[J].国际放射医学核医学杂志,2015,39(1):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
　Hu Hong,Tang Ganghua,Nie Dahong.Progress on molecular imaging of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
[9]黄娟,颜剑豪,梁联保,等.注射钆剂后弥散加权成像对乳腺肿瘤诊断的影响[J].国际放射医学核医学杂志,2015,39(4):287.[doi:10.3760/cma.j.issn.1673-4114.2015.04.003]
　Huang Juan,Yan Jianhao,Liang Lianbao,et al.Evaluation of the diffusion-weighted imaging after contrast for the characterization of breast tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):287.[doi:10.3760/cma.j.issn.1673-4114.2015.04.003]
[10]杨洋,樊赛军.LXXLL模体在雌激素受体信号通路中的作用及应用价值[J].国际放射医学核医学杂志,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
　Yang Yang,Fan Saijun.Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
[11]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
　LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[12]柳杰,刘佩芳.乳腺癌X射线征象与雌激素受体、孕激素受体和C-erbB-2表达相关性的研究进展[J].国际放射医学核医学杂志,2012,36(5):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]
　LIU Jie LIU,Pei-fang.Development of the correlation study between mammographic appearances and expression of estrogen receptor, progesterone receptor and C-erbB-2 in patients with breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]
[13]严惟力,黄钢.乳腺癌辐射抗性的影响因素及其可能作用[J].国际放射医学核医学杂志,2006,30(4):193.
　YAN Wei-li,HUANG Gang.Factors implicated to radioresistance of breast cancer and their possible roles[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(1):193.
[14]郭睿,晋建华.99mTc-depreotide生长抑素受体显像的临床应用研究[J].国际放射医学核医学杂志,2007,31(3):154.
　GUO Rui,JIN Jian-hua.The clinical application and study of 99mTc-depreotide somatostatin receptor imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(1):154.
[15]孟召伟,董峰,谭建.乳腺癌的雌激素受体显像[J].国际放射医学核医学杂志,2007,31(3):157.
　MENG Zhao-wei,DONG Feng,TAN Jian.Estrogen receptor imaging in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(1):157.

备注/Memo

备注/Memo:
收稿日期:2005-11-03。
基金项目:江苏省社会发展科技项目(BS2004507)
通讯作者:王佳琼(E-mail:jqwnmc@hotmail.com)
更新日期/Last Update: 1900-01-01